Pediatric HIV: Trial Sets Tivicay Backbone as Best First-Line Option

(MedPage Today) -- Dolutegravir (Tivicay)-based antiretroviral therapy in children with HIV infection was superior to efavirenz-based standard of care in the first-line setting in a prospective trial, researchers reported.
In her presentation...